Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
about
Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatmentsThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic targetProteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsThe resistance mechanisms of proteasome inhibitor bortezomib.Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell linesA Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology GroupIdentification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy.Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in developmentMolecular profiling of childhood cancer: Biomarkers and novel therapiesEvaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing programPhosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.Surface-tension driven open microfluidic platform for hanging droplet culture.Proteasome inhibition as novel treatment strategy in leukaemia.Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell linesPharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogsDifferential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia.Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activityProteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapyHigher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Novel targeted drug therapies for the treatment of childhood acute leukemiaProteasome inhibitors in multiple myeloma: 10 years later.Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.Proteasome inhibitors in acute leukemia.Novel targeted therapies in acute lymphoblastic leukemia.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.The role of bortezomib in the treatment of acute lymphoblastic leukemia.Genomic profiling and directed ex vivo drug analysis of an unclassifiable myelodysplastic/myeloproliferative neoplasm progressing into acute myeloid leukemia.The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.Cytokines in immunogenic cell death: Applications for cancer immunotherapy.Acute lymphoblastic leukemia: a comprehensive review and 2017 updateProteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.Evidence for the Critical Roles of NF-κB p65 and Specificity Proteins in the Apoptosis-Inducing Activity of Proteasome Inhibitors in Leukemia Cells.Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.(Immuno)proteasomes as therapeutic target in acute leukemia.Protein kinase inhibitors for acute leukemia.Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
P2860
Q28078896-76B5BDAF-CD51-459F-97B6-1D40BCDC417FQ30248842-C1288B3E-D224-402C-900A-B34EEA28FFC6Q30252776-F8A4A054-40CD-4753-931E-E6878332C4A2Q33711119-FB1050E2-22CD-4566-B652-7DF6F7114C0BQ33842215-1F356335-F7AD-40FB-B654-04C5E467B104Q34085747-15567DD0-BB73-4FF3-805F-10806946C7BFQ34256126-9C661426-3855-4D44-9C8F-CBE89E2EB2A3Q34287755-BB74E27B-D688-4EE3-B773-A9CDC4A3816EQ34585047-9C4D6AEA-BE0C-4403-B37A-05CC2EECC8FAQ35094092-738201BD-7DE2-4486-9CA9-915294B73078Q35967452-1C7C7F18-23EB-4F00-B587-D77B160D4DC3Q36250783-D68AEED8-8A32-4D6F-BDFF-B567A44377D1Q36362320-F753619F-519B-4FA5-9444-29E6DB245387Q36461618-513F9A52-F85D-4A6F-9B52-B068AC5B428BQ36462782-D335E4CC-A810-4603-93BA-230214AFDBE7Q36513273-7036E4AF-032F-4DE9-BC54-6699BC1DF680Q36849233-FF8D40A1-316F-4B93-9D9C-DDD8B9F752E8Q36858579-2F8BCCC3-63F8-48E6-8C55-8416B407D7B3Q37087261-CF99AB27-A8AF-43E7-902E-4E6CE6B4B3CCQ37089235-1AA67E2C-446B-4CF2-82E3-63B8029BE254Q37233146-5B9C4565-44F5-4F18-A362-0B6FA3EBDF6DQ37377911-D303B72D-3D36-4D33-BDF8-BF942FF9343FQ37477482-C1458337-0346-4793-A5E1-706A42329D3BQ38014395-F2839DBB-66C5-442E-9A7E-6E7CE69D0367Q38033592-DA465C8F-4A22-4DB4-ABE6-43F70D64F57EQ38088003-2C4074CB-7DD2-49CC-82F9-FD72119E9F30Q38120551-E213A343-96C9-4DDD-91FC-E0C5B4947830Q38155455-5CFAF553-8F68-4FDF-BA6D-B1FC69ECC5D0Q38833230-4BDB5BCC-29D2-4CD8-8A4D-C91010553DCAQ38860767-64852C91-B122-47EF-B35E-F4980D9536E0Q39002810-585BC555-AEDA-4339-ADEA-2B64FEA9C28CQ39397491-3F482C94-79F0-4D51-B91D-150C8A8F2943Q39406969-AD3FA537-6BEE-45FE-8FDD-D547412F1CF9Q39432416-A084D257-F205-4AC6-AF06-AB0DE98B8164Q40162776-ED13E4BA-65B1-48F4-8418-6CC2A999ED46Q45784186-0A51191E-6845-4D1F-A991-FF8D7F90277BQ47115348-35DD262A-3D20-42F0-8C00-459A06313F2BQ47131929-6DC41895-F423-4D53-B308-035E1B906BB6Q49873905-6DF5482C-AA85-47A0-BA77-D3A47D3377DDQ53377247-584598EA-E6D6-45E7-9D34-26D0E42D656C
P2860
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
@en
type
label
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
@en
prefLabel
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
@en
P2093
P2860
P1476
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
@en
P2093
Anurhadha Gannavarapu
David Z D'Argenio
Sharon E Plon
Stacey L Berg
Terzah M Horton
P2860
P2888
P356
10.1007/S00280-005-0135-Z
P577
2005-11-15T00:00:00Z
P5875
P6179
1026328818